Company

Bank

Analyst

Coverage

Opinion

Wk chg

5/30 cls

Acura Pharmaceuticals Inc. (NASDAQ:ACUR)

MLV

Graig Suvannavejh

Downgrade

Hold (from buy)

-14%

$1.06

Suvannavejh also lowered his target to $1 from $2 after Acura said FDA advised the company that data from the Phase II Study 301 are "insufficient to support an intranasal abuse deterrence claim" for Vycavert hydrocodone bitartrate/acetaminophen. In an Aug. 1, 2013, 10-Q filing, Acura had said it expected to submit an NDA to FDA for the product in 1H14. Acura said it will determine a revised timeline for the submission following a meeting with FDA. Vycavert is an oral immediate release hydrocodone tablet with acetaminophen using Aversion abuse-deterrent technology.